

PRICE INDEX · MAY 2026

# The GLP-1 Price Index.

*Independent comparison of US GLP-1 weight loss telehealth programs. Verified by completing real checkouts. Re-scored every Monday.*

**25 programs · 38 verified prices · 7 drugs**

Cheapest cash-pay: **PlushCare, \$45/mo**

Verified May 25, 2026

Editor: **John Samaras** · [press@glpchart.com](mailto:press@glpchart.com)

Cite as: *GLP Chart Price Index, May 2026.*

# Executive summary, May 2026

The GLP Chart Price Index tracks 25 US weight loss telehealth programs across seven GLP-1 medications. Every price is verified by completing a real signup on the program in question. The chart is re-scored every Monday. This edition reflects pricing as of May 25, 2026.

This month, the cheapest cash-pay all-in monthly price is **\$45/mo at PlushCare**, a compounded-semaglutide flat-rate program with no dose escalation. The cheapest cash-pay route to a branded GLP-1 is **\$199/mo at Hims & Hers**. The median program across all 25 costs **\$198/mo** cash-pay. The spread between the cheapest and most expensive programs is **11.1x**.

The pricing landscape splits cleanly into three rails. **Compounded semaglutide and tirzepatide** (503A pharmacy preparations) run \$70 to \$300/mo cash-pay and account for the bottom of the index. **Branded Wegovy and Zepbound cash-pay** through DTC telehealth runs \$199 to \$599/mo before membership fees. **Branded Ozempic cash-pay** (no diabetes diagnosis) runs \$499 to over \$1,000/mo and sits at the top of the index, the gap that drives most off-label compounded demand.

For programs that route patients to insurance with a successful prior authorization, the patient out-of-pocket can fall to \$25 to \$50/month. Those copay numbers are excluded from the cash-pay index because they depend on plan terms, not program terms, but they appear in the downloadable CSV as the “insurance route” rows.

This report distills the index into five top findings, the full price chart and the methodology. The underlying data is downloadable as CSV at [glpchart.com/price-index](https://glpchart.com/price-index).

# Top five findings, May 2026

## FINDING 1

The cheapest cash-pay GLP-1 program in the US is **PlushCare at \$45/mo**, a flat-rate compounded semaglutide program with no dose escalation. This is the floor of the market.

## FINDING 2

The cheapest cash-pay route to a branded GLP-1 is **Hims & Hers at \$199/mo** for Wegovy. Branded Zepbound through LillyDirect at \$349/mo via partner programs is the cheapest branded tirzepatide route.

## FINDING 3

The spread between the cheapest and most expensive programs is **11.1x**. That spread is the largest in any consumer-healthcare comparison category we have indexed. Same molecule, same dose, 11.1x the price.

## FINDING 4

**The median program costs \$198/mo** cash-pay across all 25 tracked. The mean runs higher than the median because of a long right tail of premium-priced programs at \$700+/mo. Half of buyers are paying under \$198/mo, but a third are paying more than \$400/mo.

## FINDING 5

Compounded semaglutide costs roughly one-third the per-milligram price of branded Wegovy at the same 2.4 mg/week maintenance dose, and roughly one-seventh the per-milligram price of branded Ozempic cash-pay. The branded vs compounded gap is the central economic question of the category, and it is widening as Lilly cuts LillyDirect cash prices to defend brand share.

# The full price index, May 2026

Every program-by-drug combination with a verified cash-pay maintenance price. Sorted by drug, then price ascending within each drug. 38 rows.

Program	Drug	Maintenance / mo	Lock-in	Score
Hims & Hers	Compounded sema	\$69-\$175/mo	Month-to-month	7.4/10
Noom Med	Compounded sema	\$129-\$199/mo	Month-to-month	7.6/10
Ro Body	Compounded sema	\$145-\$299/mo	Month-to-month	7.4/10
Strut Health	Compounded sema	\$149-\$199/mo	Month-to-month	7.4/10
Ivim Health	Compounded sema	\$150/mo	3-month minimum	7.2/10
Klarity Health	Compounded sema	\$150-\$199/mo	Per-visit	6.6/10
Push Health	Compounded sema	\$150-\$350/mo	Month-to-month	6.9/10
Mochi Health	Compounded sema	\$178/mo	Month-to-month	7.6/10
Henry Meds	Compounded sema	\$179-\$249/mo	Month-to-month	7.8/10
Medvi	Compounded sema	\$179-\$299/mo	Month-to-month	7.4/10
Found	Compounded sema	\$189/mo	12-month commitment	6.2/10
Eden	Compounded sema	\$249/mo	3-month minimum	6.4/10
Lemonaid Health	Compounded sema	\$278-\$348/mo	Month-to-month	6.8/10

Program	Drug	Maintenance / mo	Lock-in	Score
Lindora	Compounded sema	\$399/mo	Month-to-month	7.6/10
Lifeforce	Compounded sema	\$473/mo	Annual prepay option	6.5/10
Ro Body	Compounded tirz	\$199-\$349/mo	Month-to-month	7.4/10
Found	Compounded tirz	\$199-\$349/mo	12-month commitment	6.2/10
Klarity Health	Compounded tirz	\$199-\$299/mo	Per-visit	6.6/10
Strut Health	Compounded tirz	\$199-\$299/mo	Month-to-month	7.4/10
Push Health	Compounded tirz	\$200-\$450/mo	Month-to-month	6.9/10
Ivim Health	Compounded tirz	\$224/mo	3-month minimum	7.2/10
Mochi Health	Compounded tirz	\$278/mo	Month-to-month	7.6/10
Noom Med	Compounded tirz	\$299/mo	Month-to-month	7.6/10
Henry Meds	Compounded tirz	\$299-\$349/mo	Month-to-month	7.8/10
Eden	Compounded tirz	\$329/mo	3-month minimum	6.4/10
Medvi	Compounded tirz	\$349/mo	Month-to-month	7.4/10
Hone Health	Compounded tirz	\$374-\$524/mo	Month-to-month	6.8/10
Lindora	Compounded tirz	\$499/mo	Month-to-month	7.6/10

Program	Drug	Maintenance / mo	Lock-in	Score
Hims & Hers	Wegovy (branded)	\$199-\$399/mo	Month-to-month	7.4/10
Ro Body	Wegovy (branded)	\$199-\$399/mo	Month-to-month	7.4/10
Klarity Health	Wegovy (branded)	\$199-\$399/mo	Per-visit	6.6/10
LifeMD	Wegovy (branded)	\$199-\$349/mo	Month-to-month	8.1/10
Sesame Care	Wegovy (branded)	\$499/mo	Month-to-month	6.8/10
Ro Body	Zepbound (branded)	\$299-\$449/mo	Month-to-month	7.4/10
LifeMD	Zepbound (branded)	\$349-\$549/mo	Month-to-month	8.1/10
Hims & Hers	Zepbound (branded)	\$449/mo	Month-to-month	7.4/10
Sesame Care	Ozempic (branded)	\$998-\$1036/mo	Month-to-month	6.8/10
Sesame Care	Rybelsus (oral)	\$998/mo	Month-to-month	6.8/10

Branded prices are cash-pay, no insurance applied. Compounded prices are from 503A pharmacies via the program. Insurance copay rows (below \$150/mo for branded drugs) are excluded from the chart but available in the downloadable CSV at [glpchart.com/price-index](http://glpchart.com/price-index).

# Methodology

**How we collect prices.** Every price is verified by completing a real signup on the program in question and screenshotting the displayed maintenance price. Where a program lists tiered dose pricing, we report the published target-dose tier. Where a price is a range across doses, we report the range. Where a program operates a separate cash-pay rail and an insurance-routed rail, we report the cash-pay number; insurance copays are excluded because they depend on plan terms, not program terms.

**How we define maintenance dose.** Maintenance is the target therapeutic dose, not the introductory teaser. For semaglutide that is 2.4 mg/week; for tirzepatide that is the program's published target tier (typically 10 to 15 mg/week). For branded Ozempic prescribed off-label for weight loss, maintenance is 2.0 mg/week.

**How we score.** Each program is scored 1 to 10 on five dimensions: pricing transparency, cancellation terms, onboarding friction, medication options and member outcomes. The overall score is a weighted average. Pricing transparency carries the heaviest weight because it is the dimension that varies most across the chart and the one that most distorts buyer decisions. The full sub-score breakdown is in the downloadable CSV. The complete scoring rubric is at [glpchart.com/methodology](https://glpchart.com/methodology).

**How often we re-verify.** Every Monday. The Price Index dataset (CSV and PDF) is refreshed on the first Monday of each month. The chart on the live page reflects the most recent Monday re-score.

**What we exclude.** Programs that are not currently accepting US patients. Programs that require an existing insurance prior authorization to enroll. Programs that do not publish a cash-pay maintenance price. The downloadable CSV documents every exclusion.

# Editorial independence and funding

GLP Chart is an independent editorial comparison site. It is not a telehealth program, not a pharmacy, not a consultancy. We do not accept paid placements. Programs do not see their score before we publish it. We do not change scores in response to partnership outreach.

**How we make money.** Affiliate commissions on outbound clicks where the program runs an affiliate program. This is disclosed on every outbound link via the standard rel="sponsored" attribute and on every page footer. The rank order is determined before any partnership conversation. We publish programs we do not have an affiliate relationship with on equal footing.

**Editor on record.** John Samaras, founder and editor. Full-time on the US GLP-1 telehealth category since 2026. Based in Austin, Texas. No equity, no retainer, no referral arrangement with any program in the chart. Available for background and on-the-record interviews on telehealth pricing, compounded vs branded economics and prior-authorization mechanics. Email [press@glpchart.com](mailto:press@glpchart.com).

## Citation

*Cite as: GLP Chart Price Index, May 2026. [glpchart.com/price-index](https://glpchart.com/price-index). Verified May 25, 2026.*

## Reuse license

Published under Creative Commons CC BY 4.0. You may reuse, redistribute and adapt the data, the chart, the quote cards and this report, including for commercial use, with attribution to GLP Chart and a link to [glpchart.com/price-index](https://glpchart.com/price-index).

## Source documents on request

Email [press@glpchart.com](mailto:press@glpchart.com) for purchase-flow screenshots, program pricing pages and 503A pharmacy invoices that document any quoted figure in this report.